Introduction
Natural killer (NK) cells are the effector cells of innate immunity and known to play an important role in the enhancement of adaptive immune responses.
1,2 NK cells kill tumor cells by natural cytotoxicity, but they can also be activated upon binding of antibodies to Fc-receptors (CD16/ FcgRIIIa) on their surface, thereby mediating antibodydependent cellular cytotoxicity (ADCC). NK cells are not only cytotoxic but also immunoregulatory, and secrete a variety of cytokines and chemokines, such as IFN-g, TNF-a, and GM-CSF, to promote innate and adaptive immune responses. Of note, recent work has highlighted the ability of NK cells to preferentially kill cancer stem-like cells, a quiescent subpopulation described in most cancers that displays enhanced tumorigenic potential and is resistant to traditional cytoreductive therapies. 3 Thus, NK cells are important to control tumor development, and the ability of NK cells to kill tumor targets has been extensively studied in various hematological malignancies. 4, 5 While clinical results in the cure of hematological malignancies are excellent, NK-based immunotherapy against solid tumors is still limited and unsatisfactory. Since NK cells are frequently deficient or dysfunctional in cancer patients, 6 ,7 the adoptive transfer of large numbers of NK cells with full anti-tumor functionality, is an attractive therapeutic strategy. However, unlike T cell expansion, it is difficult to generate large numbers of functional NK cells.
Researchers are thus seeking to develop new methods to obtain larger populations of highly pure and functional NK cells. [8] [9] [10] [11] [12] While these methods have some merit, they have major drawbacks including: low expansion scale, low purity of NK cells, high cost, complicated procedures, and safety for human administration. We recently developed a novel clinical-grade and large-scale NK cell expansion system, using recombinant human fibronectin fragment (FN-CH296, RetroNectinV R )-induced T cells (RN-T cells) for stimulation. 13, 14 Using this method, we can generate large numbers of activated NK cells from small quantities of peripheral blood, without prior purification. Moreover, the majority of expanded cells highly express functional markers, such as NKG2D and CD16, and exert strong cytotoxicity in experimental models. 14 In our previous clinical trial of NK cell monotherapy using this method, we confirmed that this novel expansion system is effective at producing large numbers of fully functional NK cells even in patients with advanced cancers, and adoptive transfer of these NK cells is safe and very well tolerated. 13 Immune monitoring demonstrated that cytotoxicity of peripheral blood was elevated approximately two-fold up to 4 weeks after NK cell administration, however, definite clinical responses were not observed in patients treated with NK monotherapy. This observation emphasizes the need for combination strategies to fully exploit the potential of adoptive NK cells using this expansion method.
Monoclonal antibody therapy has emerged as an important therapeutic modality and has been utilized in a variety of human cancers. Several mechanisms have been proposed for the ability of anti-cancer antibodies to mediate their effects. Monoclonal antibodies, such as trastuzumab and cetuximab, bind extracellular tumor antigens to prevent ligand binding, resulting in apoptosis and inhibition of cell growth. Another main hypothesized mechanism is mediated by ADCC in Fc-receptor-bearing cells. Prior clinical studies employing trastuzumab or cetuximab have indeed indicated that ADCC contributes to the antitumor effects elicited by such antibodies. In patients treated with trastuzumab, a correlation was found between clinical responses and in vitro ADCC activity 15 or increased numbers of NK cells. 16 In colorectal cancer, cetuximab is significantly more effective in patients with NK cell-infiltrated tumors, while there was no such significant association in patients treated without cetuximab. 17 Although multiple immune effector cell types are involved in the clearance of antibody-coated tumors from the body, 18 these are often deficient and dysfunctional in cancer patients. 6, 7 In addition, due to cytotoxic treatment regimens in cancer patients, the immune system can be temporarily dysfunctional, with a decrease in immune effector cell subsets. 19 Since NK cells appear to play a key role in ADCC activity, such limitations could theoretically be overcome by adoptive NK cell therapy, but this approach has yet to be evaluated in clinical trials. Moreover, the high expression of CD16 on expanded NK cells generated using our method would be expected to enhance the efficacy of IgG1 monoclonal antibodies in adoptive NK therapy, by augmenting ADCC. The present phase I clinical trial evaluated the safety, toxicity, and immunological response of the administration of NK cells generated by our novel system, in combination with trastuzumab or cetuximab in patients with advanced gastric or colorectal cancer, respectively.
Methods

Eligibility
Patients with un-resectable, locally advanced, and/or metastatic gastric or colorectal cancer, who had been administered IgG1 antibody or were scheduled for administration, were enrolled in this study. Patients were recruited between July 2014 and January 2017. Eligibility criteria included: histologically confirmed gastric or colorectal adenocarcinoma; age greater than 20 and less than 80 years; Eastern Cooperative Oncology Group (ECOG) performance status 2; life expectancy of at least 4 months; absence of serious cardiovascular disease; adequate vital organ function, as indicated by a leukocyte count of 3,000/mm 3 and <12,000/mm 3 ; neutrophil count 1,500/mm 3 ; platelet count 100,000/mm 3 ; hemoglobin 9.0 g/dL; serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) 100 IU/L; serum total bilirubin 2 mg/dL; and serum creatinine 1.5 mg/dl. Patients were excluded if they: tested positive for hepatitis B or C virus, HIV, HTLV-1, or syphilis infection; had other active severe infection; had serious complications, such as severe diabetes mellitus, unstable angina, or myocardial infarction within 6 months of registration; were pregnant or lactating;
What's new? Cell-mediated and antibody-based approaches have each emerged as promising cancer treatments. Here the authors combined both approaches and performed a first clinical trial of adoptive therapy with natural killer cells together with monoclonal antibodies trastuzumab or cetuximab. The treatment was well tolerated and three out of six patients with advanced gastric or colorectal cancer showed a decrease in tumor size. The results support the concept that antibody-dependent cellular cytotoxicity might be enhanced with combination treatment, yielding favorable responses not observed with monotherapies.
or had a medical history of severe hypersensitivity or autoimmune disease. 
Study design
Cell processing
We have previously established an efficient method for largescale expansion of fully functional NK cells. 13 This approach uses autologous FN-CH296 (RetroNectin V R )-stimulated T (RN-T) cells to generate pure NK cells on a large-scale, without prior purification from small amounts of blood. Our NK cell expansion method is described in the following sections.
Preparation of RN-T cells. Peripheral blood (10-20 mL) was taken from each cancer patient. RN-T cells were prepared using a previously described method. 20 Briefly, peripheral blood mononuclear cells (PBMCs) were separated using Ficoll-Paque PREMIUM (GE Healthcare, Tokyo, Japan). Subsequently, 2 3 10 6 cells were re-suspended in GT-T551 culture medium (Takara Bio), containing heat-inactivated autologous plasma (0.5%) and recombinant IL-2 (Proleukin; NovartisPharma, Nuremberg, Germany), then transferred to cell-culture plates coated with both anti-CD3 mAb (OKT3; Takara Bio) and FN-CH296. On Day 4, the cells were transferred to CultiLife V R 215 bags (Takara Bio), and diluted with GT-T551 medium containing plasma (0.5%) and IL-2, which was then changed every 3 or 4 days. Cells were cultured for 1-2 weeks, g-irradiated, and then used as stimulators for NK-cell expansion.
Large-scale expansion of NK cells. PBMCs were obtained from the peripheral blood (40-100 mL) of each cancer patient. Subsequently, 5.6 3 10 6 PBMCs were re-suspended in LymphoONE NK culture medium supplemented with heat-inactivated autologous plasma (1.0%), IL-2, and OK-432 (Picibanil; Chugai Pharmaceutical Co, Tokyo, Japan). Cells were then transferred to a CultiLife V R 215 bag and RN-T cells, as stimulators, were added. On Day 7, the cultured cells were stimulated again using RN-T cells in LymphoONE NK culture medium, supplemented with heat-inactivated autologous plasma (1.0%) and IL-2. On Day 11, the cells were transferred to a CultiLife V R Eva bag (Takara Bio), and LymphoONE NK containing plasma (1.0%) and IL-2 were added. Cells were then expanded by adding LymphoONE NK medium and increasing the number of CultiLife V R Eva bags as necessary. On days 18-24, the cultured cells were harvested, washed and cryopreserved. After thawing and wash, the cells were re-suspended in 100 mL of a solution supplemented with 1-5% human serum albumin (Albuminar; CSL Behring, PA), then administered to patients immediately.
Quality control was conducted by assessing samples taken during the culture period and the final product. Sterility tests and endotoxin tests were contracted to FALCO Biosystems (Kyoto, Japan). The BacT/ALERT (bioM erieux, Durham, NC) microbiological detection system was used for sterility, and a kinetic turbidimetric LAL assay was used for endotoxin. Mycoplasma contamination tests were performed either by a MycoAlert Mycoplasma Detection Kit (Lonza Japan, Tokyo, Japan), or by real-time PCR method using specific primer/probe sets for mycoplasma. The viability of expanded cells was measured by trypan blue exclusion assay. After thawing, a small aliquot of the final product was used for in vitro cytotoxicity assays; these were tested by flow cytometry to assess the proportions of CD3
2 CD56 1 cells and other cell surface markers.
Treatment protocol
Chemotherapy and NK cell transfer were given every 3 weeks. In patients with gastric cancer, capecitabine 1,000 mg/ m 2 or S-1 80 mg/m 2 were given orally twice a day for 14 days followed by a 1-week rest, and cisplatin 80 mg/m 2 was given on Day 1 by intravenous infusion. Trastuzumab was given by intravenous infusion at a dose of 8 mg/kg on Day 1 of the first cycle, followed by 6 mg/kg every 3 weeks. In patients with colorectal cancer, capecitabine 1,000 mg/m 2 or S-1 80 mg/m 2 were given orally twice a day for 14 days followed by a 1-week rest, and oxaliplatin 130 mg/m 2 was given on Day 1 by intravenous infusion. Cetuximab was given by intravenous infusion at a dose of 400 mg/m 2 on Day 1 of the first cycle, followed by 250 mg/m 2 every 3 weeks. Expanded NK cells that passed quality tests were intravenously injected for 60 min, 3 days after IgG1 antibody administration, every 3 weeks for 3 cycles (Fig. 1) . The eligibility criteria for transferred cells were as follows: (i) cultured cell viability was greater than 80%; (ii) mean purity of the three sets of cultured cells was greater than 50%; (iii) the numbers of transferred cells were 70-130% of the number specified for each cohort. Patients were divided into three groups, consisting of three to four patients each: Cohort 1, 0.5 3 10 9 cells per dose; Cohort 2, 1.0 3 10 9 cells per dose;
and Cohort 3, 2.0 3 10 9 cells per dose. We investigated the dose-limiting toxicity (DLT) occurring over a 28-day period after the third cell infusion. DLT was defined as grade 3 for any adverse event related to the administration of cultured cells. If no DLT was observed in the previous cohort, another
Cancer Therapy and Prevention
Ishikawa et al.
cohort was treated at the next higher dose. There was no intra-patient dose escalation in this study.
Phenotypic analysis
The phenotype of expanded cells and PBMCs at baseline (before chemotherapy), 1 week after the first administration of NK cells (follow-up 1), or 1 week (follow-up 2) and 4 weeks after the third administration (follow-up 3) were analyzed by flow cytometry (Fig. 1 ). Monoclonal antibodies specific for CD3, CD16, CD56 (Beckman Coulter, CA), NKG2D, PD-1, TIGIT (eBioscience, CA), CXCR3 (R&D system, MN), CXCR4 (Becton Dickinson, CA), CX3CR1 (Bio Legend, CA), and LAG3 (Enzo Life Science, NY) were used. Each monoclonal antibody was conjugated as follows: CD16, CD69, CXCR3, and LAG3 with fluorescein isothiocyanate (FITC); NKG2D, CXCR4, CX3CR1, PD-1, and TIGIT with phycoerythrin (PE); CD3 with phycoerythrin-Cyanin 5 (PE-Cy5); and CD56 with phycoerythrin-Cyanin 7 (PC7-Cy7). Cells were analyzed with a Cytomics FC500 (Beckman Coulter) and data were acquired using CXP software version 2.2 (Beckman Coulter), according to the manufacturer's instructions.
Whole blood and serum cytokine assays
Blood samples were obtained from patients at baseline (before chemotherapy), 1 week after the first administration of NK cells (follow-up 1), or 1 week (follow-up 2) and 4 weeks after the third administration (follow-up 3) (Fig. 1) . Whole blood cytokine assays, except IFN-a, were conducted according to procedures described previously. 21, 22 Heparinized whole blood was diluted fourfold with Eagle's minimal essential medium (Nissui Pharmaceutical Co., Ltd., Tokyo, Japan) and stimulated with phytohemagglutinin (25 lg/mL). Samples were incubated at 378C for 48 hr, after which the supernatants were harvested by centrifugation at 800g for 10 min, and they were then stored at 2808C until analysis. Cytokine levels in the samples were measured with a multiplex cytokine array system (Bio-Plex; Bio-Rad Laboratories, Inc., Hercules, CA) according to the manufacturer's instructions. The Multiplex Th1/Th2 bead kit (Bio-Rad Laboratories, Inc.) was used to measure the following cytokines: IL-2, IL-4, IL-5, IL-10, IL-12(p70), IL-13, Tumor Necrosis Factor (TNF)-a, IFN-g, and granulocyte-monocyte colonystimulating factor (GM-CSF). Data acquisition and analysis were conducted with the Bio-Plex Manager Software (version 5.0). Methods for quantifying IFN-a production in whole human blood have been described previously. 23 Briefly, heparinized peripheral blood was cultured with Sendai virus (500 HA/mL) within 8 hr of taking the blood. The bloodvirus mixture was incubated at 378C for 20 hr, and IFN-a activity in the supernatant was quantified by bioassay. All serum samples were stored at 2808C until they were analyzed. Following the manufacturer's instructions, we used a Bio-Plex multiplex cytokine array system with a panel that quantified the following 27 cytokines: IL-1b, IL-1RA, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p70), IL-13, IL-15, IL-17, basic FGF, eotaxin, G-CSF, GM-CSF, IFN-g, IP-10, MCP-1, MIP-1a, MIP-1b, PDGF-BB, RANTES, TNFa, and VEGF.
In vitro cytotoxicity assay
Cytotoxicity of expanded NK cells (cryopreserved final products) against the K-562 cell line was assayed using Calcein-AM (Dojindo Molecular Technologies). Briefly, expanded NK cells were added to cell culture wells in RPMI 1640 medium with 5% FBS. Target cells (K-562) were labeled with Calcein-AM, then placed into 96-well tissue culture plates with NK Figure 1 . Study design. Expanded NK cells were intravenously injected 3 days after IgG1 antibody administration every 3 weeks for 3 cycles. We investigated adverse events occurring over a 28-day period after the third cell infusion. To test immune function, venous blood was obtained from subjects before the start of therapy (baseline), 1 week after the first administration of NK cells (follow-up 1), or 1 week (follow-up 2), and 4 weeks (follow-up 3) after the third administration. [Color figure can be viewed at wileyonlinelibrary.com] cells at various effector-to-target (E:T) ratios. After incubating for 4 hr at 378C under 5% CO 2 , the time-course for release of Calcein was measured using a fluorescence microplate reader. Cytotoxicity was calculated as follows: % cytotoxicity 5 100 3 (experimental release 2 spontaneous release)/(maximum release 2 spontaneous release). Finally, we calculated the E:T ratio needed to reduce the cytotoxicity of expanded NK cells by 50% of the maximum lysis value (EC50).
To assess the ADCC activity of expanded NK cells, NCI-N87 (HER2-overexpressed human gastric carcinoma), or A431 (EGFR-overexpressed human epidermoid carcinoma) target cell lines were labeled with Calcein-AM, then treated with trastuzumab (10 lg/mL) or cetuximab (10 lg/mL), respectively. Expanded NK cells were then added as effector cells at various effector-to-target (E:T) ratios. The release of Calcein was measured and the cytotoxicity was calculated as described above.
Clinical outcomes after combination therapy
Safety and toxicity were determined based on regular patient interviews, physical examination, and laboratory tests. Safety was assessed and reported according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0). Objective tumor response was assessed by computed tomography scans in accordance with the Response Evaluation Criteria in Solid Tumor (RECIST VERSION 1.1) criteria. Disease assessment was performed at baseline and every 4 weeks after the final treatment.
Statistical analysis
Data were analyzed using paired t tests and Dunnett's multiple comparison tests. The p values of <0.05 were considered statistically significant. Statistical analysis was performed using GraphPad Prism 5 for Windows (GraphPad, San Diego, CA).
Results
Patient characteristics
Between July 2014 and January 2017, nine eligible patients (three males and six females) were enrolled in this trial. Demographic characteristics of the enrolled patients are listed in Table 1 . The median age was 65.0 years (range: 34-79). Three patients (33.3%) had gastric cancer and six (66.7%) had colorectal cancer. All patients had an Eastern Cooperative Oncology Group (ECOG) performance status score of 1 or less. Of the nine patients, seven had received prior chemotherapies before entering the clinical trial (1 line, n 5 2; 2 lines, n 5 1; 3 lines, n 5 2; 4 lines, n 5 2). All patients except one, received three NK cell administrations. One patient (no. 9) had disease progression during the NK cell preparation period and therefore received only two administrations of NK cells.
Phenotypic characterization of expanded NK cells
In our study, the mean NK cell proportion (CD3 13 we confirmed that final product elicited by our expansion method is composed of a highly pure population of NK cells with high levels of functional markers.
Cytotoxicity of expanded NK cells
We directly tested the cytotoxicity of each patient's final product using the standard K-562 cell line, which is a NKsensitive target. Expanded cells from all patients exerted strong cytotoxic activity against K-562 (Supporting Information Fig. 2 ). At a 6.25:1 effector to target (E:T) cell ratio, an average of 99.3% of K562 cells were killed by the expanded cells, with the mean EC50 value (the E:T ratio needed to reduce cytotoxicity by 50% of the maximum value) being 1.1 6 0.5 (Supporting Information Table 2 ). We also checked the ADCC activity of each patient's final product using NCI-N87 (a HER2-positive cell line) and A431 (an EGFR positive cell line). Cytotoxicity of expanded NK cells alone against these target cells was relatively low. However, coincubation with trastuzumab or cetuximab resulted in a significant increase in NCI-N87 and A431 cell death, respectively (Supporting Information Fig. 3 ). The mean EC50 for ADCC activity in NCI-N87 cells with trastuzumab was 3.6 6 2.4, and in A431 cells with cetuximab it was 11.4 6 11.0 (Supporting Information Table 2 ). As shown Supporting Information Table  2 , EC50 values for expanded NK cells against these two cell lines in the absence of IgG1 antibodies, were greater than 100 in all cases except one (patient no. 8). Thus, expanded NK cells exerted ADCC activity, both in NCI-N87 cells exposed to trastuzumab, and in A431 cells exposed to cetuximab.
Safety assessment
In this trial, to make it easier to distinguish the side effects of chemotherapeutic drugs and IgG1 antibodies from those of
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expanded NK cell administration, patients received one course of chemotherapy combined with IgG1 antibody, and then three courses of combination therapy with NK cell therapy (Fig. 1) . Overall adverse events reported in our study are summarized in Table 2 . Grade 3 neutropenia, lymphopenia, and anemia were observed one patient each, with these being attributed to the effects of chemotherapeutic agents. The grade 3 ALP elevation observed in patient no. 6 was caused by cancer progression. Grade 3 anorexia, nausea, fatigue, and dyspnea were each observed in a single patient (no. 9), with these attributed to the progression of colon cancer; this patient thus received only two rounds of NK cell administration before the treatment protocol was discontinued. Most hematological or non-hematological adverse events of grade 2 or less were caused by the chemotherapeutic drugs or IgG1 antibodies; most of them were transient and were alleviated by the withdrawal of these agents. The frequency and severity of toxicities did not increase with dose escalation of the infused cells, and there were no severe or unexpected toxicities related to NK cell administration. Thus, a maximum tolerated dose (MTD) was not reached.
Clinical efficacy
For efficacy assessment, computed tomography (CT) was performed before and after NK cell administration. One patient (no. 9) was not evaluable due to incomplete treatment. Of the remaining eight patients, two (no. 2 and 8) had no target lesions according to RECIST criteria. Consequently, treatment response was evaluated by CT in a total of six patients. Compared to baseline, target lesion diameters 4 weeks after the last NK cell administration were found to have decreased in three patients (nos. 3, 4, and 5; Fig. 2 ). But these three patients did not achieve an objective partial response (PR) according to RECIST criteria. Of the three patients with an increase in tumor burden, two patients (nos. 1 and 6) demonstrated an increase in size of greater than 20% in their existing lesions, while new tumors were detected in patient no. 6 during treatment.
Of the six evaluable patients, four (66.7%) demonstrated stable disease (SD) and two (33.3%) demonstrated progressive disease (PD). Thus, the response rate and the disease control rate (DCR, complete response 1 PR 1SD) in our study were 0 and 66.7%, respectively (Table 3) . Median time to progression (TTP) after starting NK cell administration of the four patients with SD was 267.5 days (range: 130-664). The TTP of patient nos. 3, 4, and 5 with tumor shrinkage was 664, 304, and 231 days, respectively. Of the two patients without target lesions, serum carcinoembryonic antigen (CEA) levels in patient no. 8 were found to have decreased after starting NK cell administration (29.5 ! 21.2 ng/mL), and stable disease was maintained for 4 months after the final NK cell infusion. Consequently, of the eight patients who completed treatment, a total of four (50%) showed some degree of clinical response (i.e., a decrease in the size of target lesions or in the serum level of CEA).
Immunological monitoring
We and others have reported that whole blood cytokine production assays have some advantages compared to assays that use isolated PBMCs. 22, 24 The whole blood assay can evaluate the function of immune cells in peripheral blood, and thus captures the influence of serum factors such as IL-10. 24 Thus, the whole blood assay is a more comprehensive tool for evaluating patients' actual immune responses. As shown Supporting Information Table 3 , the whole blood cytokine assay in our study revealed that the levels of all cytokines, except for GM-CSF, increased after administration of NK cells. The levels of GM-CSF were below the detection limit in most patients. It is noteworthy that levels of IFN-g and IL-2, 7 days after NK cell administration (follow-up 1), Table 2 . Maximum toxicity per patient
All cohort (n 5 
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were significantly increased compared to baseline (4.5-fold and 2-fold, respectively; Figs. 3a and 3b) . Both the IFN-g / IL-4 and IFN-g / IL-10 ratios from follow-up 1 were also increased significantly (Figs. 3c and 3d) . These results indicate that the combination of adoptive NK cell therapy and IgG1 antibodies could strongly enhance a Th1-type immune response.
Overall, there was no significant change in serum cytokine levels after treatment (Supporting Information Table 4 ). However, when we analyzed patients with measurable target lesions, serum IL-6 and IL-8 levels were found to increase in patients with tumor growth following treatment, whereas they were found to decrease in patients with tumor shrinkage. The relative change in the levels of IL-6 and IL-8, from baseline to follow-up 3, was higher in patients with tumor growth, than in patients with tumor shrinkage (Supporting Information Fig. 4) . Finally, in regard to regulatory T cells (Tregs), both the number and proportion of these cells in peripheral blood decreased following treatment. Although these changes did not reach statistical significance, the trend was found to continue during follow up (Figs. 3e and 3f) .
Discussion
This phase I trial of IgG1 monoclonal antibodies and autologous NK cell therapy, derived using our novel expansion method, demonstrated that the combination was very well tolerated, with no unexpected toxicities. To the best of our knowledge, this is the first clinical study of the combination of IgG1 monoclonal antibodies and adoptive NK therapy. We confirmed the enhancement of Th1-type immunological responses using whole blood cytokine production assays. Moreover, it is noteworthy that clinical responses to the combination therapy were observed in four out of the eight advanced cancer patients who completed the protocol treatment, despite most of these patients receiving several prior treatments.
In our study, we were able to generate pure NK cell populations (median 92.9%) on a large scale without prior purification, and show that these cells highly expressed functional markers (CD16 and NKG2D) and chemokine receptors (CXCR3, CXCR4, and CX3CR1). These results are similar to those of our previous clinical study. 13 We confirmed that CD16 expression in NK cells decreased approximately 30% after thawing, compared to fresh samples.
14 In the present study, the percentage of CD161 NK cells in the final product was relatively high (median 69.6%), despite using thawed samples. There were three cases (nos. 3, 4, and 5) with extremely high levels of CD161 cells (>90%), and it is noteworthy that, in each of these cases, tumor sizes were reduced after treatment. Although expanded NK cells also expressed immune checkpoint molecules such as LAG3 (median 35.3%) and TIGIT (median 81.0%), we observed that these cells were highly cytotoxic against the K562 cell line in vitro, and also showed ADCC activity against the NCI-N87 and A431 cell line when combined with either trastuzumab or cetuximab, respectively. There was some variation in the strength of ADCC activity between patients. However, expanded NK cells from all nine patients showed enhanced tumor cytotoxicity in combination with IgG1 antibodies in vitro.
The primary focus of this clinical trial was to assess safety, and we demonstrated that the addition of adoptive NK cell therapy to combined IgG1 monoclonal antibody treatment and chemotherapy did not increase toxic effects. The most common adverse events were anemia, thrombocytopenia, fatigue, and peripheral neuropathy, which occurred at similar rates to those previously described with doublet chemotherapy regimens (i.e., S-1 1 Cisplatin, S-1 1 Oxaliplatin, and Capecitabine 1 Oxaliplatin), or the combination of trastuzumab or cetuximab with these chemotherapy regimens. [25] [26] [27] [28] Grade 3 adverse events attributed to the effects of chemotherapy in our study were neutropenia, lymphopenia, fatigue, anorexia, and nausea. Grade 3 ALP elevation was seen in a patient with significant liver metastases (no. 6), and grade 3 dyspnea was seen in one patient with increasing pleural effusion (no. 9); both of these episodes were considered to be related the progression of tumor. Although cardiac adverse events have been reported in patients treated with trastuzumab, these were not observed in the present trial. Dermatitis acneiform was observed in all patients treated with cetuximab, but no grade 3 dermatitis was observed. In summary, adoptive NK cell therapy was not found to enhance trastuzumab-or cetuximab-related toxicities. Although clinical response was not a primary endpoint in our study, we did observe clinical benefit in four patients (target lesions decreased in size in three patients, and serum CEA levels decreased in one patient). In patients with clinical responses, long lasting disease stabilization was observed after completion of the protocol treatment. Despite the fact that patients in this trial were advanced cancer cases, most of whom had received several prior treatments, some clinical responses could be noted. Patient no. 4 had been heavily pretreated (4 chemotherapy lines), and had also previously received cetuximab in combination with 5-FU and oxaliplatin. Nevertheless, the tumors of this patient decreased by >15% after the combination therapy. Similarly, Bertino et al. have recently demonstrated that lenalidomide, which can stimulate the proliferation and activation of NK cells, improved single-agent activity of cetuximab in patients pretreated with cetuximab. 29 These results suggest that enhancement of NK cell function may overcome resistance to IgG1 antibodies, and thus have the greatest benefit in patients who have had prior exposure to these antibody therapies. Moreover, it has been reported that NK cells can enhance in vitro cytotoxicity of cetuximab, even against RAS and BRAF mutant colorectal cancer cells. 30 It would be interesting to explore the combination of adoptive NK cell therapy and cetuximab for RAS and BRAF mutant colorectal cancer patients.
Serial changes in immunological parameters were monitored in our study. Whole blood cytokine assays revealed that the levels of all cytokines increased after administration of NK cells. Notably, whole blood IFN-g production 7 days after NK cell administration increased approximately 4.5-fold on average compared to baseline, with high levels persisting for as long as 4 weeks after the third NK cell administration, when they were approximately twofold higher than baseline. Both IFN-g/IL-4 and IFN-g/IL-10 ratios were also significantly increased by treatment. Previous studies have demonstrated that IFN-g plays an important role in cancer immunotherapy, and IFN-g expression of immune cells is considered to be highly correlated with therapeutic success. 31, 32 Moreover, we have previously demonstrated that whole blood IFN-g levels are an effective measure of clinical responses to cancer immunotherapy. 22, 33 However, such Th1-type responses were not observed in our prior clinical study of NK cell monotherapy.
Other researchers have reported that NK cells enhance IFN-g secretion when given in combination with IgG1 monoclonal antibodies. 34, 35 These data suggest that the combination of NK therapy and IgG1 antibodies may enhance the ability of NK cells to secrete IFN-g in a clinical setting. The findings of the current study suggest that adoptive NK therapy combined with IgG1 antibodies can not only enhance ADCC, but also lead to NK cell Th1 cytokine secretion, and that this Th1-type response may therefore lead to, and enhance, adaptive immune responses. Such immunological responses would be expected to be associated with a clinical benefit.
Tregs could theoretically interfere with NK cell activation through membrane-bound TGF-b 36 and by competing for IL-2 availability. 37 In the present study, we found that peripheral Tregs decreased after combination therapy. Consistent with this observation, Yang et al. recently demonstrated that activated allogeneic NK cell therapy can reduce the Treg population in peripheral blood. 38 Moreover, they demonstrated that adoptive NK therapy reduced not only Tregs, but also myeloid-derived suppressor cells (MDSC) in peripheral blood. These results suggest that ex vivo-activated NK cells have a novel role in overcoming the negative function of immune suppressor cells, through unknown mechanisms. Further studies are required to examine the interaction between NK cells and Tregs or MDSCs in greater depth.
The small number of patients must be taken into consideration as a major limitation of our study. In addition, we did not check the in vivo trafficking of intravenously administered NK cells, which is an important issue for the adoptive cell transfer therapy of solid tumors. However, the therapeutic efficacy of current combination therapies remain unsatisfactory, and novel approaches are therefore required. Various strategies have been proposed to enhance adoptive NK cell therapy, 39 including: (i) augmentation of anti-tumor responses using cytokines (e.g., IL-15, IL-18, and IL-21), activating receptor agonists (e.g., anti-41BB agonistic antibodies), inhibitory receptor antagonist (e.g., blocking antibodies to KIR, TIM3), and immunomodulatory agents (e.g., lenalidomide); (ii) modifying the immune suppressive tumor microenvironment (e.g., with the use of a lympho-depleting conditioning chemotherapy prior to NK cell administration); and (iii) enhancement of NK cell trafficking to the tumor (e.g., via modulation of NK cell homing receptors, or direct intratumoral NK cell injection). Such innovations are the key to enhancing NK cell adoptive therapy to the point where it can be applied to a variety of solid tumors.
In conclusion, our study is the first to highlight the feasibility of the combination of adoptive NK therapy and IgG1 monoclonal antibodies in advanced cancer patients. The combination therapy was shown to be safe and feasible. Moreover, we confirmed favorable clinical and immunological responses in our study. However, given the limited activity observed in this clinical trial, additional studies are necessary to continue to develop these combination approaches using the methods detailed above, and thus further enhance their clinical benefit.
